- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01292382
Effects of rTMS on the Cognition of Elderly With Mild Memory Complaints (TMSMemOld)
Effects of rTMS on the Cognition of Elderly With Cognitive Impairment no Dementia ( CIND )
Memory is constituted by a set of mental abilities of information processing that will be available at a later time. Flawless performance depends on several brain systems and other cognitive domains. Normal aging is characterized by cognitive deficits that may worsen the production capacity and quality of life. Such deficits represent variations of normal , and may stabilize,or even better progress. Include multiple cognitive domains, such as working and episodic memory, and attention. Despite the heterogeneity of the nature and severity of these deficits, common characteristics were observed in neuropsychological assessment of that population, for example, reduction in processing speed. There is an important gap in the therapeutic approach of these individuals.
Transcranial magnetic stimulation (TMS) is a noninvasive and promising intervention, with potential to improve memory and cognition activating networks that operate on memory or other networks that interfere with cognitive performance. The technique relies on generating a variable magnetic field originated from an alternating electric current applied to the human skull reaching focal cortical regions.
This study is a sham-controlled clinical trial, randomized, double-blind study. It will be evaluated the effects of repetitive transcranial magnetic stimulation (rTMS) on global cognition (memory, attention, language, executive functions, planning, logical reasoning, calculation and visual-spatial perception), especially memory, of elderly individuals with mild cognitive impairment, included in the domain of cognitive impairment no dementia (CIND).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects:
I. Eligibility criteria:
- Male and female participants
- Older adults aged 60-74 years
- Education ≥ 4 years
- Performance on neuropsychological tests below normal for age and education
- Availability to attend the sessions of the application of TMS and neuropsychological assessments
- Signing an informed consent by the participant or his guardian
II. No eligibility criteria:
- Prior diagnosis of dementia
- Any psychiatric disorder, except for mild depression in remission for at least 6 months. Shall be excluded those with scores > 12 on the Hamilton Depression Scale
- History of neurosurgery and implantation of metal clips, head trauma, implantation of cardiac pacemakers, stroke, transient ischemic attack, cardiac surgery
- Clinical or neurological diseases with impact on cognitive ability
- Neurodegenerative central nervous system disease(eg. Parkinson Disease)
- Alcohol and other drug abstinence for less than one year
- Use of psychotropic medications (anticholinergic, mood stabilizers, neuroleptics), except for antidepressants
- Chronic use of benzodiazepines with abstinence for less than 6 months
- Severe uncontrolled organic disease that might interfere with the conduct of the study, such as cancer, congestive heart disease, digestive disorders, diabetes mellitus type I or type II, dyslipidemia etc.
- Sensory impairments(to guarantee a adequate performance in the tests to evaluate cognitive functions)
- Magnetic resonance imaging of the brain with evidence of lacunar or large vessels infarctions, cerebral hemorrhage
13. Hachinski Ischemic score of > 7 (or modified by Loeb > 5) 14. Any other condition that in the opinion of the investigator becomes problematic inclusion of the patient in a trial of this nature, as well as patients who do not adhere or do not cooperate.
III. Outcome measures:
Will be considered as an outcome measure a variation greater than or equal to 10% compared to baseline scores of neuropsychological tests, which will be applied on three occasions: immediately before (T0), after treatment (T2) and 4 weeks after the end of it (T3).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Sao Paulo, Brazil, 05453-010
- Recruiting
- University of Sao Paulo General Hospital
-
Contact:
- Hellen Marra
- Phone Number: +55 11 3069 8159
- Email: hellen.marra@usp.br
-
Contact:
- Marco Marcolin
- Phone Number: +55 11 3069 8159
- Email: marcolin@usp.br
-
Principal Investigator:
- Marco Marcolin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants of both sexes
- Aged between 60 and 74 years
- Schooling ≥ 4 years
- Performance on neuropsychological tests of up to 1.5 standard deviations below normal for age and education
- Signing an informed consent by the participant or his guardian.
Exclusion Criteria:
- Prior diagnosis of dementia.
- Any psychiatric disorder, except for mild depression for at least six months.
- Shall be excluded those with scores> 12 on the Hamilton scale.
- History of neurosurgery and implantation of metal clips, head trauma, implantation of cardiac pacemakers, stroke, transient ischemic attack, cardiac surgery
- Clinical or neurological diseases with an impact on cognitive ability
- Neurodegenerative central nervous system (eg Parkinson's disease)
- Alcohol and other drug dependency with abstinence for less than a year
- Use of psychotropic medications (anticholinergic, mood stabilizers, neuroleptics), except for antidepressants
- Chronic use of benzodiazepines with abstinence for less than six months
- Use of vitamin supplements (multivitamins, folic acid, vitamin B12), ginkgo biloba
- Severe uncontrolled organic disease that could interfere in the conduct of the study, such as cancer, heart disease, digestive disorders, diabetes mellitus type I or type II, uncontrolled dyslipidemia etc.
- Sensory disabilities, intellectual, preventing them from adequately perform the necessary tests to assess cognitive function
- Cerebrovascular disease based on Hachinsky score.
- History of head trauma.
- Any other condition that in the opinion of the investigator makes problematic the inclusion of the patient in a trial of this nature, as well as patients who do not adhere or not to cooperate.
- Worsening of the primary symptoms during the treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: rTMS versus Sham
rTMS: active coil Sham: inactive coil
|
Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
Other Names:
Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
Other Names:
|
|
Active Comparator: rTMS versus sham
rTMS group: active coil Sham group: inactive coil
|
Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
Other Names:
Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repetitive transcranial magnetic stimulation improves memory in elderly with memory complaints
Time Frame: Neuropsychological tests: T1 - effects after rTMS, and T2: 4 weeks after rTMS
|
Neuropsychological tests - RBMT (Rivermead Behavioral and Memory Test)
|
Neuropsychological tests: T1 - effects after rTMS, and T2: 4 weeks after rTMS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repetitive transcranial magnetic stimulation improves global cognition of elderly with memory complaints
Time Frame: Neuropsychological tests: T1 - effects after rTMS, and T2: 4 weeks after rTMS
|
Performance on neuropsychological tests - STROOP, Trails 1 and 2, mini mental status exam (MMSE), clock drawing test, Wechsler, WAISS III, verbal fluency.
|
Neuropsychological tests: T1 - effects after rTMS, and T2: 4 weeks after rTMS
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marco Marcolin, University of Sao Paulo General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- rTMSCogOld
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Singapore General HospitalSingapore Health ServicesNot yet recruitingMild Cognitive Impairment (MCI) | Mild Cognitive Impairment
-
Xuanwu Hospital, BeijingNot yet recruitingMild Cognitive Impairment (MCI)China
-
The Hong Kong Polytechnic UniversityJohns Hopkins University; The University of Hong Kong; University of ReadingNot yet recruitingMild Cognitive Impairment (MCI)Hong Kong
-
Universidad Complutense de MadridAB Biotics, SANot yet recruitingMild Cognitive Impairment (MCI)Spain
-
University of SheffieldNot yet recruitingMild Cognitive Impairment (MCI)United Kingdom
-
The Hong Kong Polytechnic UniversityRecruitingMild Cognitive Impairment (MCI)Hong Kong
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.TerminatedMild Cognitive Impairment (MCI)Taiwan
Clinical Trials on Repetitive transcranial magnetic stimulation
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Aalborg UniversityActive, not recruitingAerobic Exercise | Repetitive Transcranial Magnetic Stimulation (rTMS)Denmark
-
Yanghua TianEnrolling by invitationInsomnia | Generalized Anxiety Disorder (GAD) | Repetitive Transcranial Magnetic Stimulation (rTMS)China
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
Universitat de LleidaNot yet recruitingCerebral Palsy, SpasticSpain
-
The University of Hong KongNot yet recruiting
-
Yi YangRecruitingTranscranial Magnetic StimulationChina